Information for patients
GeNeuro is developing a new approach to treating MS by seeking to block mechanisms suspected of causing inflammation and neurodegeneration, rather than interfering with the body's immune response. This approach is the result of 25 years of research into human endogenous retroviruses (HERVs), including 15 years within the Institut Mérieux group and INSERM, before GeNeuro was founded in 2006.
That research led to the discovery of a potentially causal factor of multiple sclerosis: the MSRV-Env protein, which is expressed by genes that are normally silent. The presence of MSRV-Env in patients' brains could cause the inflammation and neurodegeneration that characterise MS.
GeNeuro has therefore developed GNbAC1, a monoclonal antibody currently in phase IIb of clinical development, as a treatment for multiple sclerosis. GNbAC1 neutralises MSRV-Env rather than targeting the patient's immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease's progress in all its forms.